^
Association details:
| Biomarker: | EGFR fusion |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | fexagratinib (ABSK091) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Molecular analysis for therapy choice (MATCH) arm W: Phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway.
Published date:
05/16/2018
Excerpt:
Patients (Pts) were screened by NGS for FGFR aberrations including amplification (≥7x), mutation, and fusion. 70/5558 (1.3%)....Pts were divided into three groups: amplification (Amp) (n = 21), single nucleotide variant (SNV) (n = 20), or fusion (n = 9). Best confirmed response for the three groups are shown in the table below….AZD4547 demonstrated modest activity across various solid tumors with aberrations in FGFR pathway with acceptable toxicities.
DOI:
10.1200/JCO.2018.36.15_suppl.2503
Trial ID:
